APEPTICO is an innovative biotech company that develops new peptide-based medicinal drugs for the therapeutic and prophylactic treatment of severe and chronic diseases.

Our mission is to translate structural elements of well-characterised proteins and biopharmaceuticals into pre-clinically and clinically validated peptides.

All our products address highly profitable and growing markets.

The patent “Prevention and Treatment of Hyperpermeability” invented and owned by APEPTICO ranks among the 10 most innovative inventions of the year 2011 in Austria.

APEPTICO Announces Successful Completion of Phase I Trial with AP301 in Oedematous Respiratory Failure.

The Annual Congress of the European Respiratory Society (Amsterdam, 2011) has been a major success for APEPTICO's development compound AP301.

Vienna, Austria, September 09^th, 2011: APEPTICO today announced that it will present significant research results of its inhalation therapy for prevention and treatment of Oedematous Respiratory Failure at the 2011 Annual Congress of the European Respiratory Society.

Meet APEPTICO at the Bio International Convention (June 27^th - 30^th, 2011) in Washington DC. APEPTICO will exhibit at the Austrian Pavilion #3137 in Hall A and will present latest findings of the AP301 clinical study in the Company Presentation event.

Vienna, Austria, April 07, 2011 - APEPTICO today announced the initiation of a Phase I clinical trial with its lead product AP301 to assess the safety and tolerability of the orally inhaled peptide drug. AP301 is being developed for the treatment of oedematous respiratory failure in patients suffering from lung infection, lung injury and lung transplantation.

The 2010 Annual Conference of the European Respiratory Society was a major success for APEPTICO: Three presentations of its lead compound AP301.

Meet APEPTICO at the 2010 Annual Conference of the European Respiratory Society (September 18^th - 22^nd, 2010) in Barcelona and at the Bio-Europe in Munich (November 15^th - 17^th, 2010).

01^st July, 2010. APEPTICO's lead molecule AP301 has been validated in the porcine model of lung injury by inhalation of the peptide-aerosol.

05^th August, 2010, Vienna, Austria: APEPTICO Forschung und Entwicklung GmbH, a biotechnology company developing novel peptide-based drugs, today announced completion of a €3 million financing round.

23^rd February, 2010. APEPTICO's lead molecule AP301 has been validated in the experimental lung transplantation model to prevent ischemia reperfusion injury.

10^th February, 2010. APEPTICO granted Orphan Drug Designation by FDA for development compound AP301.

APEPTICO will present the company and development products at the BioSquare (February 1^st-2^nd, 2010) and Bio-Europe Spring (March 8^th-10^th, 2010).

Meet APEPTICO at the Science4Life Messe in Frankfurt (October 22^nd, 2009) and the Bio-Europe in Vienna (November 2^nd-4^th, 2009).

08^th September, 2009. APEPTICO presents its lead product AP301 at the Annual Congress of the European Respiratory Society in Vienna, Austria.

20^th July, 2009. APEPTICO granted Orphan Medicinal Product Designation by EMEA for lead product AP301.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Tel +43 (0)664 1432919  |  Mail office@apeptico.com